Literature DB >> 23628322

The effect of liver transplantation on fatigue in patients with primary biliary cirrhosis: a prospective study.

Marco Carbone1, Sally Bufton, Andrea Monaco, Laura Griffiths, David E Jones, James M Neuberger.   

Abstract

BACKGROUND & AIMS: The role of liver transplantation (LT) for the relief of fatigue in patients with primary biliary cirrhosis (PBC) is unclear, and while many centers exclude fatigue as an indication for transplantation, there have been no studies to prospectively evaluate the impact of LT on fatigue. We aimed at assessing the severity of fatigue in LT candidates with PBC and the impact of LT on fatigue.
METHODS: In a prospective, longitudinal study, we used the PBC-40 questionnaire in 49 adult patients with PBC at listing and at 6, 12, and 24 months after LT and in two sex- and age-matched cohorts of community controls and non-transplanted PBC patients. Correlation analysis was used to assess the relationship between liver function and fatigue. ANOVA was used to compare the variation of fatigue score before and after LT.
RESULTS: There was no correlation between MELD and fatigue before LT (r(2)=0.01). Overall, the fatigue score after LT was substantially lower than before LT, falling from 40.7 ± 11.4 pre-transplant to 27.7 ± 9.5, 28.7 ± 10.1, 26.2 ± 10.1 (p<0.0001) at 6, 12, and 24 months after LT, respectively. The same improvement of fatigue was observed in both low-MELD (<17) and high-MELD (≥ 17) patients. Improvement in fatigue was also evident in the comparison with a "non-transplant PBC" control group (31.1 ± 11.6, p=0.03). However, 44% of the total cohort, and 47% of those with low-MELD, for whom the probability of dying of LT may be higher than that of dying without LT, had moderate to severe fatigue (defined as a fatigue score ≥ 29) at two years after LT. Moreover, fatigue scores at two years were higher in the transplant PBC cohort compared to a cohort of community controls (17.8 ± 5.9, p<0.0001).
CONCLUSIONS: Liver transplantation is associated with improvement in fatigue in patients with PBC. However, a substantial proportion of patients continue to suffer from significant fatigue after two years. Whether the improvement is enough to justify organ allocation in patients with fatigue alone, without liver failure, is still an open issue. Certainly, in the era of organ shortage, with many patients dying waiting for a graft, this may not represent the optimal use of donated deceased organs.
Copyright © 2013 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  AMA; AZA; CMV; CNS; Fatigue; HRQoL; LT; Liver transplantation; MELD; MMF; Model for End-Stage Liver Disease; PBC; PBC-40; PRED; Primary biliary cirrhosis; QOL; Quality of life; SD; TAC; UKELD; United Kingdom Model for End-Stage Liver Disease; antimitochondrial antibodies; azathioprine; central nervous system; cytomegalovirus; health-related quality of life; liver transplantation; mofetil mycophenolate; prednisone; primary biliary cirrhosis; quality of life; standard deviation; tacrolimus

Mesh:

Year:  2013        PMID: 23628322     DOI: 10.1016/j.jhep.2013.04.017

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  19 in total

1.  A Practical Review of Primary Biliary Cholangitis for the Gastroenterologist.

Authors:  Fernanda Q Onofrio; Gideon M Hirschfield; Aliya F Gulamhusein
Journal:  Gastroenterol Hepatol (N Y)       Date:  2019-03

2.  The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines.

Authors:  Gideon M Hirschfield; Jessica K Dyson; Graeme J M Alexander; Michael H Chapman; Jane Collier; Stefan Hübscher; Imran Patanwala; Stephen P Pereira; Collette Thain; Douglas Thorburn; Dina Tiniakos; Martine Walmsley; George Webster; David E J Jones
Journal:  Gut       Date:  2018-03-28       Impact factor: 23.059

3.  Treatment of Fatigue in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis.

Authors:  Jennifer Y Lee; Christopher J Danford; Hirsh D Trivedi; Elliot B Tapper; Vilas R Patwardhan; Alan Bonder
Journal:  Dig Dis Sci       Date:  2019-01-10       Impact factor: 3.199

Review 4.  Recent advances in the development of farnesoid X receptor agonists.

Authors:  Ahmad H Ali; Elizabeth J Carey; Keith D Lindor
Journal:  Ann Transl Med       Date:  2015-01

Review 5.  Fatigue in Cirrhosis.

Authors:  Krishnagopal Bhandari; Dharmesh Kapoor
Journal:  J Clin Exp Hepatol       Date:  2021-09-04

Review 6.  Fatigue in chronic liver disease patients: prevalence, pathophysiology, and management.

Authors:  Artur Kośnik; Maciej Wójcicki
Journal:  Prz Gastroenterol       Date:  2022-03-18

7.  The impact of osteoporosis on health-related quality of life in patients after liver transplantation - a pilot study.

Authors:  Joanna Raszeja-Wyszomirska; Robert Kucharski; Katarzyna Kotarska; Marta Zalewska; Tomasz Miazgowski
Journal:  Prz Gastroenterol       Date:  2015-06-19

8.  Fatigue and related factors after liver transplantation.

Authors:  Kwangpyo Hong; Hyeyoung Kim; Jeong-Moo Lee; Kwang-Woong Lee; Nam-Joon Yi; Hae Won Lee; YoungRok Choi; Suk-Won Suh; Suk Kyun Hong; Kyung Chul Yoon; Hyo-Sin Kim; Kyung-Suk Suh
Journal:  Korean J Hepatobiliary Pancreat Surg       Date:  2015-11-30

9.  Patients with primary biliary cholangitis and fatigue present with depressive symptoms and selected cognitive deficits, but with normal attention performance and brain structure.

Authors:  Roman Zenouzi; Janina von der Gablentz; Marcus Heldmann; Martin Göttlich; Christina Weiler-Normann; Marcial Sebode; Hanno Ehlken; Johannes Hartl; Anja Fellbrich; Susanne Siemonsen; Christoph Schramm; Thomas F Münte; Ansgar W Lohse
Journal:  PLoS One       Date:  2018-01-10       Impact factor: 3.240

10.  Early Molecular Stratification of High-risk Primary Biliary Cholangitis.

Authors:  Claire Hardie; Kile Green; Laura Jopson; Ben Millar; Barbara Innes; Sarah Pagan; Dina Tiniakos; Jessica Dyson; Muzlifah Haniffa; Venetia Bigley; David E Jones; John Brain; Lucy J Walker
Journal:  EBioMedicine       Date:  2016-11-21       Impact factor: 8.143

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.